The Use and Refinement of Rodent Models in Anti-cancer Drug Discovery: A Review : RefinementCURWEN, Jon O; WEDGE, Stephen R.ATLA. Alternatives to laboratory animals. 2009, Vol 37, Num 2, pp 173-180, issn 0261-1929, 8 p.Article

AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerWEDGE, Stephen R; KENDREW, Jane; CHESTER, Rosemary et al.Cancer research (Baltimore). 2005, Vol 65, Num 10, pp 4389-4400, issn 0008-5472, 12 p.Article

Effect of Pretreatment With Atenolol and Nifedipine on ZD6126-lnduced Cardiac Toxicity in RatsGOULD, Sarah; WESTWOOD, F. Russell; CURWEN, Jon O et al.Journal of the National Cancer Institute. 2007, Vol 99, Num 22, pp 1724-1728, issn 0027-8874, 5 p.Article

Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitorsHENNEQUIN, Laurent F; STOKES, Elaine S. E; THOMAS, Andrew P et al.Journal of medicinal chemistry (Print). 2002, Vol 45, Num 6, pp 1300-1312, issn 0022-2623Article

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administrationWEDGE, Stephen R; OGILVIE, Donald J; GRAHAM, George A et al.Cancer research (Baltimore). 2002, Vol 62, Num 16, pp 4645-4655, issn 0008-5472Article